<DOC>
	<DOCNO>NCT00934817</DOCNO>
	<brief_summary>The pharmacokinetics glimepiride metformin HCl compare single dose intake combination order answer follow question : - Is Amaryl-M 1/500 mg ( Test tablet ) proportional Amaryl-M 2/500 mg tablet regard glimepiride component ? - Is Amaryl-M 1/500 mg ( Test tablet ) tolerable compare Amaryl-M 2/500 mg ?</brief_summary>
	<brief_title>Dose Proportionality Study Comparing Amaryl-M 1/500 mg Amaryl-M 2/500 mg</brief_title>
	<detailed_description>16 subject randomize 2 sequence group different treatment order study drug period . Only healthy volunteer screen test medical inquiry , physical examination , clinical laboratory test , etc . within 4 week ( -28d ~ -1d ) prior drug administration ( 1d ) determine eligible study select randomized screen 1 day prior first administration study medication ( -1d ) . Then , subject admit clinical research center Seoul National University Hospital 9 p.m. -1d , allow take anything except water . After one week washout period , subject go second phase treatment period administer accord treatment order crossover way . For subject complete study , post-study visit test perform designated time pass .</detailed_description>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age : Between 19 45 year age , inclusive ( age base date give inform consent ) Ideal body weight ( Broca index ) : 50 90 kg , inclusive , within ±20 % Ideal Body Weight , [ ( Height cm100 ) ×0.9 ] Subjects appropriate participate study judge clinical laboratory physical examination take within 4weeks prior start study Subjects able abstain caffeine caffeinecontaining product ( e.g. , coffee , cola , tea , chocolate ) , grapefruit grapefruit containing product , alcohol smoking within 7 day dose hospitalization Subjects give inform consent voluntarily participate study History allergy include drug allergy , except untreated , asymptomatic , seasonal allergy time dose Use medication consider acceptable clinical investigator last 10 day period start day study Use inducer inhibitor metabolize enzyme last 28 day start day study . History significant clinical illness need medical caution , include cardiovascular , immunologic , hematologic , neuropsychiatric , respiratory , gastrointestinal , hepatic , renal disease chronic disease History significant surgical resection gastrointestinal tract except appendectomy Abnormal clinical laboratory finding , especially AST ALT &gt; 1.25 fold , total bilirubin &gt; 1.5 fold upper normal level Pregnant lactate woman woman childbearing potential without medically acceptable birth control study Evidence alcohol abuse ( define regular alcohol intake exceeds 24 oz [ 675 ml ] beer , 12 oz [ 340 ml ] wine 160 ml soju 3 oz [ 85 ml ] hard liquor per day [ e.g. , brandy , whiskey , gin ] ) drug abuse Heavy smoker ( &gt; 10 cigarette per day ) , ca n't quit smoke hospitalization Participation clinical trial drug within 3 month prior start study Donation 200ml whole blood within 4 week 400ml within 12 week prior start study Positive Hepatitis B surface antigen ( HBsAg ) , Hepatitis C antibody ( HCV Ab ) , HIV antibody Judged inappropriate study investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Volunteer</keyword>
</DOC>